Verrica Pharmaceuticals (VRCA) Payables (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Payables of $2.2 million for Q1 2026, up 51.98% year-over-year from $1.4 million in Q1 2025, and up 5.84% quarter-over-quarter from $2.1 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Payables (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Payables history runs 10 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- In Q1 2026, Payables rose 51.98% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (up 51.98% YoY), while the FY2025 annual figure was $2.1 million, up 9.28% from the prior year.
- Payables for Q1 2026 stood at $2.2 million, up from $2.1 million in the prior quarter.
- The five-year high for Payables was $43.0 million in Q2 2022, with the low at $137000.0 in Q3 2022.
- The 5-year median for Payables is $1.9 million (2023), against an average of $6.4 million.
- The sharpest annual moves came in 2022 and 2023: Payables tumbled 99.68% in 2022, then soared 1305.11% in 2023.
- Verrica Pharmaceuticals' Payables stood at $507000.0 in 2022, then jumped by 386.0% to $2.5 million in 2023, then declined by 23.05% to $1.9 million in 2024, then advanced by 9.28% to $2.1 million in 2025, then gained by 5.84% to $2.2 million in 2026.
- Business Quant data shows VRCA's Payables at $2.2 million in Q1 2026, $2.1 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 35.57 Mn |
| 10 | Verrica Pharmaceuticals | 102.29 Mn | 91.09 Mn | - | 1.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.60 Mn |
| Mar 31, 2026 | 2.19 Mn |
| Dec 31, 2025 | 2.07 Mn |
| Sep 30, 2025 | 1.59 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 1.90 Mn |
| Sep 30, 2024 | 966,000.00 |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 2.53 Mn |
| Dec 31, 2023 | 2.46 Mn |
| Sep 30, 2023 | 1.93 Mn |
| Jun 30, 2023 | 2.06 Mn |
| Mar 31, 2023 | 575,000.00 |
| Dec 31, 2022 | 507,000.00 |
| Sep 30, 2022 | 137,000.00 |
| Jun 30, 2022 | 43.01 Mn |
| Mar 31, 2022 | 42.53 Mn |
| Dec 31, 2021 | 42.54 Mn |
| Sep 30, 2021 | 42.25 Mn |